Healthcare - Biotechnology - NASDAQ - US
$ 26.63
-5.06 %
$ 3.91 B
Market Cap
-12.05
P/E
CASH FLOW STATEMENT
-214 M
OPERATING CASH FLOW
-360 K
INVESTING CASH FLOW
472 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Immunovant, Inc.
| Net Income | -259 M |
| Depreciation & Amortization | 231 K |
| Capital Expenditures | -360 K |
| Stock-Based Compensation | 41.1 M |
| Change in Working Capital | 2.63 M |
| Others | 2.54 M |
| Free Cash Flow | -215 M |
Cash Flow
Millions
| Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (259.3) | (211.0) | (156.7) | (107.4) | (66.4) | (28.6) | (136.7) |
| Depreciation & Amortization | 0.2 | 0.2 | 0.1 | 65 K | 21 K | 10 K | 0 |
| Deferred Income Tax | 0 | 0 | 0 | (0.3) | 0 | 0 | 0 |
| Stock Based Compensation | 41.1 | 32.3 | 34.2 | 18.8 | 7.0 | 1.3 | 1.8 |
| Other Operating Activities | 1.1 | 1.1 | 1.1 | 0.9 | 1.2 | (0.8) | 5.2 |
| Change in Working Capital | 2.6 | (10.9) | 15.1 | 4.6 | 4.8 | (0.5) | 1.4 |
| Cash From Operations | (214.2) | (188.2) | (106.1) | (83.3) | (53.4) | (28.5) | (128.3) |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | (0.4) | (0.2) | (0.3) | (0.2) | 31 K | 52 K | 0 |
| Other Items | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | (0.4) | (0.2) | (0.3) | (0.2) | 31 K | 52 K | 0 |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 37.9 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (0.3) | 0.4 | 200.1 | 383.1 | 109.1 | 35.6 | 128.3 |
| Cash From Financing Activities | 472.4 | 70.9 | 200.1 | 383.1 | 147.0 | 35.6 | 128.3 |
| CHANGE IN CASH | |||||||
| Net Change In Cash | 258.8 | (117.3) | 93.7 | 299.6 | 93.6 | 7.0 | 0 |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (214.6) | (188.4) | (106.4) | (83.5) | (53.4) | (28.6) | (128.3) |